PL393578A1 - Przeciwnowotworowe białko fuzyjne - Google Patents

Przeciwnowotworowe białko fuzyjne

Info

Publication number
PL393578A1
PL393578A1 PL393578A PL39357811A PL393578A1 PL 393578 A1 PL393578 A1 PL 393578A1 PL 393578 A PL393578 A PL 393578A PL 39357811 A PL39357811 A PL 39357811A PL 393578 A1 PL393578 A1 PL 393578A1
Authority
PL
Poland
Prior art keywords
fusion protein
domain
sequence
terminus
anticancer fusion
Prior art date
Application number
PL393578A
Other languages
English (en)
Other versions
PL219845B1 (pl
Inventor
Jerzy Szczepan Pieczykolan
Sebastian Dominik Pawlak
Bartłomiej Żerek
Piotr Kamil Rózga
Original Assignee
Adamed Spółka Z Ograniczoną Odpowiedzialnością
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adamed Spółka Z Ograniczoną Odpowiedzialnością filed Critical Adamed Spółka Z Ograniczoną Odpowiedzialnością
Priority to PL393578A priority Critical patent/PL219845B1/pl
Priority to RS20170597A priority patent/RS56095B1/sr
Priority to SI201230978T priority patent/SI2661496T1/sl
Priority to LTEP12700215.2T priority patent/LT2661496T/lt
Priority to KR1020137020558A priority patent/KR101950043B1/ko
Priority to ES12700215.2T priority patent/ES2628377T3/es
Priority to JP2013547859A priority patent/JP5797773B2/ja
Priority to BR112013016980-0A priority patent/BR112013016980B1/pt
Priority to US13/978,090 priority patent/US9175059B2/en
Priority to MX2013007872A priority patent/MX339203B/es
Priority to CN201280003863.3A priority patent/CN103228788B/zh
Priority to PL12700215T priority patent/PL2661496T3/pl
Priority to NZ609219A priority patent/NZ609219B2/en
Priority to MEP-2017-131A priority patent/ME02756B/me
Priority to EP12700215.2A priority patent/EP2661496B1/en
Priority to PT127002152T priority patent/PT2661496T/pt
Priority to PCT/EP2012/050145 priority patent/WO2012093158A1/en
Priority to HUE12700215A priority patent/HUE032576T2/en
Priority to DK12700215.2T priority patent/DK2661496T3/en
Priority to EA201391005A priority patent/EA025830B1/ru
Priority to CA2814597A priority patent/CA2814597C/en
Priority to AU2012204900A priority patent/AU2012204900B2/en
Priority to SG2013032768A priority patent/SG190049A1/en
Priority to UAA201309548A priority patent/UA108778C2/ru
Publication of PL393578A1 publication Critical patent/PL393578A1/pl
Priority to IL226205A priority patent/IL226205B/en
Publication of PL219845B1 publication Critical patent/PL219845B1/pl
Priority to HRP20170905TT priority patent/HRP20170905T1/hr
Priority to CY20171100632T priority patent/CY1119149T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/49—Platelet-derived growth factor [PDGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/515—Angiogenesic factors; Angiogenin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1808—Epidermal growth factor [EGF] urogastrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PL393578A 2011-01-05 2011-01-05 Przeciwnowotworowe białko fuzyjne PL219845B1 (pl)

Priority Applications (27)

Application Number Priority Date Filing Date Title
PL393578A PL219845B1 (pl) 2011-01-05 2011-01-05 Przeciwnowotworowe białko fuzyjne
MEP-2017-131A ME02756B (me) 2011-01-05 2012-01-05 Fuziona belančevina protiv raka
CA2814597A CA2814597C (en) 2011-01-05 2012-01-05 Anticancer fusion protein
LTEP12700215.2T LT2661496T (lt) 2011-01-05 2012-01-05 Priešvėžinis sulietas baltymas
KR1020137020558A KR101950043B1 (ko) 2011-01-05 2012-01-05 항암 융합 단백질
ES12700215.2T ES2628377T3 (es) 2011-01-05 2012-01-05 Proteína de fusión antineoplásica
JP2013547859A JP5797773B2 (ja) 2011-01-05 2012-01-05 抗がん性融合タンパク質
BR112013016980-0A BR112013016980B1 (pt) 2011-01-05 2012-01-05 Proteína de fusão anticancerígena
US13/978,090 US9175059B2 (en) 2011-01-05 2012-01-05 Anticancer fusion protein comprising trail and a growth factor receptor inhibitor
MX2013007872A MX339203B (es) 2011-01-05 2012-01-05 Proteina de fusion anticancer.
CN201280003863.3A CN103228788B (zh) 2011-01-05 2012-01-05 抗癌融合蛋白
PL12700215T PL2661496T3 (pl) 2011-01-05 2012-01-05 Przeciwnowotworowe białko fuzyjne
NZ609219A NZ609219B2 (en) 2011-01-05 2012-01-05 Anticancer fusion protein
RS20170597A RS56095B1 (sr) 2011-01-05 2012-01-05 Fuziona belančevina protiv raka
EP12700215.2A EP2661496B1 (en) 2011-01-05 2012-01-05 Anticancer fusion protein
EA201391005A EA025830B1 (ru) 2011-01-05 2012-01-05 Слитый белок против злокачественной опухоли
PCT/EP2012/050145 WO2012093158A1 (en) 2011-01-05 2012-01-05 Anticancer fusion protein
HUE12700215A HUE032576T2 (en) 2011-01-05 2012-01-05 Anti-cancer fusion protein
DK12700215.2T DK2661496T3 (en) 2011-01-05 2012-01-05 FUSION PROTEIN AS ANTICANCING AGENT
PT127002152T PT2661496T (pt) 2011-01-05 2012-01-05 Proteína de fusão anticancerígena
SI201230978T SI2661496T1 (sl) 2011-01-05 2012-01-05 Fuzijski protein proti raku
AU2012204900A AU2012204900B2 (en) 2011-01-05 2012-01-05 Anticancer fusion protein
SG2013032768A SG190049A1 (en) 2011-01-05 2012-01-05 Anticancer fusion protein
UAA201309548A UA108778C2 (xx) 2011-01-05 2012-05-01 Протираковий злитий протеїн
IL226205A IL226205B (en) 2011-01-05 2013-05-07 Fusion proteins, pharmaceutical preparations containing them and their use in the preparation of drugs for the treatment of cancer
HRP20170905TT HRP20170905T1 (hr) 2011-01-05 2017-06-13 Antikancerogeni fuzijski protein
CY20171100632T CY1119149T1 (el) 2011-01-05 2017-06-15 Αντικαρκινικη πρωτεϊνη συντηξης

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL393578A PL219845B1 (pl) 2011-01-05 2011-01-05 Przeciwnowotworowe białko fuzyjne

Publications (2)

Publication Number Publication Date
PL393578A1 true PL393578A1 (pl) 2012-07-16
PL219845B1 PL219845B1 (pl) 2015-07-31

Family

ID=45476512

Family Applications (2)

Application Number Title Priority Date Filing Date
PL393578A PL219845B1 (pl) 2011-01-05 2011-01-05 Przeciwnowotworowe białko fuzyjne
PL12700215T PL2661496T3 (pl) 2011-01-05 2012-01-05 Przeciwnowotworowe białko fuzyjne

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL12700215T PL2661496T3 (pl) 2011-01-05 2012-01-05 Przeciwnowotworowe białko fuzyjne

Country Status (25)

Country Link
US (1) US9175059B2 (pl)
EP (1) EP2661496B1 (pl)
JP (1) JP5797773B2 (pl)
KR (1) KR101950043B1 (pl)
CN (1) CN103228788B (pl)
AU (1) AU2012204900B2 (pl)
BR (1) BR112013016980B1 (pl)
CA (1) CA2814597C (pl)
CY (1) CY1119149T1 (pl)
DK (1) DK2661496T3 (pl)
EA (1) EA025830B1 (pl)
ES (1) ES2628377T3 (pl)
HR (1) HRP20170905T1 (pl)
HU (1) HUE032576T2 (pl)
IL (1) IL226205B (pl)
LT (1) LT2661496T (pl)
ME (1) ME02756B (pl)
MX (1) MX339203B (pl)
PL (2) PL219845B1 (pl)
PT (1) PT2661496T (pl)
RS (1) RS56095B1 (pl)
SG (1) SG190049A1 (pl)
SI (1) SI2661496T1 (pl)
UA (1) UA108778C2 (pl)
WO (1) WO2012093158A1 (pl)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105051067B (zh) 2013-03-12 2020-04-17 分子模板公司 用于引起细胞内化的cd20结合免疫毒素及其使用方法
WO2014141094A1 (en) 2013-03-14 2014-09-18 Adamed Sp. Z O.O. Anticancer conjugate
EP2995626B1 (en) 2013-05-06 2018-07-11 China Pharmaceutical University Bifunctional fusion proteins to inhibit angiogenesis in tumour microenvironment and to activate adaptive immune responses and the genes and uses thereof
KR102514910B1 (ko) 2014-01-27 2023-03-29 몰레큘러 템플레이츠, 인코퍼레이션. 폴리펩티드를 전달하는 mhc 클래스 i 항원결정기
US10421958B2 (en) 2014-02-05 2019-09-24 Molecular Templates, Inc. Methods of screening, selecting, and identifying cytotoxic recombinant polypeptides based on an interim diminution of ribotoxicity
US11142584B2 (en) 2014-03-11 2021-10-12 Molecular Templates, Inc. CD20-binding proteins comprising Shiga toxin A subunit effector regions for inducing cellular internalization and methods using same
EP3137488B1 (en) 2014-06-11 2019-01-02 Molecular Templates, Inc. Protease-cleavage resistant, shiga toxin a subunit effector polypeptides and cell-targeting molecules comprising the same
AU2016215205B2 (en) 2015-02-05 2021-10-21 Molecular Templates, Inc. Multivalent CD20-binding molecules comprising shiga toxin a subunit effector regions and enriched compositions thereof
WO2016127346A1 (zh) * 2015-02-11 2016-08-18 四川大学华西医院 一种肿瘤坏死因子相关凋亡诱导配体变异体及其制备方法和用途
EP3303373B1 (en) 2015-05-30 2020-04-08 Molecular Templates, Inc. De-immunized, shiga toxin a subunit scaffolds and cell-targeting molecules comprising the same
US20210008208A1 (en) 2016-12-07 2021-01-14 Molecular Templates, Inc. Shiga toxin a subunit effector polypeptides, shiga toxin effector scaffolds, and cell-targeting molecules for site-specific conjugation
CN110536695B (zh) 2017-01-25 2024-05-10 分子模板公司 包括去免疫化的志贺毒素a亚基效应子和cd8+ t细胞表位的细胞靶向分子
EP3573652A1 (en) 2018-04-17 2019-12-04 Molecular Templates, Inc. Her2-targeting molecules comprising de-immunized, shiga toxin a subunit scaffolds

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU676476B2 (en) 1992-04-29 1997-03-13 Georgetown University Binding peptides which interact with ligand growth factors of the epidermal growth factor receptor and erbB-2-receptor
AU708239B2 (en) 1995-06-29 1999-07-29 Immunex Corporation Cytokine that induces apoptosis
JPH11513249A (ja) * 1995-09-27 1999-11-16 メディカル・リサーチ・カウンシル プロテアーゼにより開裂可能なタンパク質を組込んだ組換えウイルス
US7786282B2 (en) * 2001-12-06 2010-08-31 The Regents Of The University Of California Nucleic acid molecules encoding TNF-α ligand polypeptides having a CD154 domain
DE10247755B4 (de) 2002-10-14 2006-01-19 Pfizenmaier, Klaus, Prof. Dr. Selektive, lokale Aktivierung von Mitgliedern der TNF-Rezeptorfamilie durch systemisch inaktive nicht-Antikörper-TNF-Liganden-Fusionsproteine
CN1257187C (zh) * 2003-10-22 2006-05-24 上海恰尔生物技术有限公司 钙网蛋白－肿瘤坏死因子相关凋亡诱导配体的融合蛋白及其制法和用途
US7431915B2 (en) * 2003-10-31 2008-10-07 The Regents Of The University Of California Peptides whose uptake by cells is controllable
DE60336353D1 (de) 2003-11-03 2011-04-21 Beijing Sunbio Biotech Co Ltd Rekombinantes protein mit krebsunterdrückender wirkung, sein codierendes gen und seine verwendung
CN1256347C (zh) * 2003-12-10 2006-05-17 中国人民解放军第二军医大学 激肽原第五结构域－肿瘤坏死因子相关凋亡诱导配体的融合蛋白及其制法和用途
ATE540318T1 (de) 2005-08-16 2012-01-15 Genentech Inc Apoptosesensitivität gegenüber apo2l/trail mittels testen auf galnac-t14-expression in zellen/gewebe
US20090131317A1 (en) 2007-06-22 2009-05-21 Affymax, Inc. Compounds and peptides that bind the trail receptor
GB0723059D0 (en) 2007-11-23 2008-01-02 Nat Univ Ireland Improved cytokine design
GB0724532D0 (en) 2007-12-17 2008-01-30 Nat Univ Ireland Trail variants for treating cancer
CL2009001191A1 (es) 2008-05-14 2010-07-02 Genentech Inc Uso del peptido apo2l/trail porque sirve para preparar un medicamento para tratar el cancer de pulmon y el linfoma de hodkin.
JP5475766B2 (ja) * 2008-06-30 2014-04-16 ユニバーシティ オブ ペンシルベニア Ｆｎ１４／ＴＲＡＩＬ融合タンパク質
PL391627A1 (pl) 2010-06-25 2012-01-02 Adamed Spółka Z Ograniczoną Odpowiedzialnością Przeciwnowotworowe białko fuzyjne
RS54057B1 (en) * 2010-12-03 2015-10-30 Adamed Sp. Zo.O. ANTIKANCERSKI PROTEIN FUNCTIONS

Also Published As

Publication number Publication date
AU2012204900B2 (en) 2014-12-18
US20130288963A1 (en) 2013-10-31
ES2628377T3 (es) 2017-08-02
IL226205A0 (en) 2013-07-31
KR101950043B1 (ko) 2019-02-19
SI2661496T1 (sl) 2017-09-29
ME02756B (me) 2018-01-20
CN103228788B (zh) 2016-09-07
BR112013016980B1 (pt) 2022-10-11
DK2661496T3 (en) 2017-07-03
KR20140036143A (ko) 2014-03-25
MX339203B (es) 2016-05-13
SG190049A1 (en) 2013-06-28
CN103228788A (zh) 2013-07-31
AU2012204900A1 (en) 2013-05-02
PT2661496T (pt) 2017-06-26
CY1119149T1 (el) 2018-02-14
US9175059B2 (en) 2015-11-03
PL219845B1 (pl) 2015-07-31
CA2814597C (en) 2019-01-08
NZ609219A (en) 2014-06-27
HRP20170905T1 (hr) 2017-09-08
LT2661496T (lt) 2017-07-10
WO2012093158A1 (en) 2012-07-12
HUE032576T2 (en) 2017-09-28
PL2661496T3 (pl) 2017-08-31
EP2661496B1 (en) 2017-03-15
IL226205B (en) 2018-10-31
EA025830B1 (ru) 2017-02-28
EP2661496A1 (en) 2013-11-13
UA108778C2 (xx) 2015-06-10
CA2814597A1 (en) 2012-07-12
BR112013016980A2 (pt) 2020-08-04
RS56095B1 (sr) 2017-10-31
EA201391005A1 (ru) 2013-11-29
MX2013007872A (es) 2013-07-30
JP2014504868A (ja) 2014-02-27
JP5797773B2 (ja) 2015-10-21

Similar Documents

Publication Publication Date Title
PH12014501083A1 (en) Anticancer fusion protein
MX339203B (es) Proteina de fusion anticancer.
MX2013006213A (es) Proteina de funsion anticancer.
MX2014008028A (es) Proteina de fusion anticancerigena.
WO2013152351A3 (en) Fusion polypeptides and methods of use thereof
RU2021134101A (ru) Модифицированная j-цепь
NZ629843A (en) Identification of channelrhodopsin-2 (chop2) mutations and methods of use
TW201613958A (en) MIC-1 fusion proteins and uses thereof
MX360208B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX360211B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX363136B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
EP3363458A3 (en) A peptide
MX2021000030A (es) Metodos y composiciones que utilizan polipeptidos variantes klotho.
WO2012143477A3 (en) Anticancer fusion protein
WO2010011952A3 (en) Flip death effector domain derived peptides for inducing autophagy
PH12017500742A1 (en) Statherin peptides
EP2552462A4 (en) CCN3 PEPTIDES AND ANALOGS THEREOF FOR THERAPEUTIC USE
WO2016007919A3 (en) Antibody fragments for detecting cancer and methods of use
MX2013003168A (es) Anticuerpo contra ephrin b2 y su uso.
BR112018001207A2 (pt) novo peptídeo e uso do mesmo
AR079370A1 (es) Uso de peptidos antimicrobianos para el tratamiento de infeccion urinaria/cistitis
GB201019467D0 (en) Therapeutic agent
UA108911C2 (xx) Протираковий злитий протеїн
TH159052A (th) ฟิวชั่นโปรตีนต้านมะเร็ง (Anticancer fusion protein)